ClinicalTrials.gg
TerminatedNCT00767715Updated Oct 7, 2008

A Study in the Treatment of Acute Mania

A Phase 4 interventional study of olanzapine and haloperidol in Bipolar Disorder, sponsored by Eli Lilly and Company. Terminated at 1 site in Sweden. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2008-10-07.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Why this study was terminated
Trial discontinued due to low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.

Enrollment
28th of 28
11 · median 120
Started
2004
with 4 others
Phase 4
19 of 28
none open now
Registered
24th of 28
by date
Lead sponsor
13 of 28
Eli Lilly and Company

Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 28th largest by enrollment, is one of 5 that started in 2004, is one of 19 in phase 4, and was the 24th registered.

Bipolar Disorder

1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies testing olanzapine in Bipolar Disorder as a file.
02

Study summary

The purpose of this study is to test the efficacy and total costs of olanzapine versus commonly used conventional antipsychotics in Sweden.

Read the detailed description

The primary objective is to show that the efficacy of olanzapine is non-inferior to the conventional antipsychotics haloperidol or zuclopentixol in the treatment of an acute manic or mixed episode of bipolar disorder. Efficacy is defined as time to remission, as measured by the total scores of the Young Mania Rating Scale (Y-MRS), MADRS-S, and Clinical Global Impression - Bipolar (CGI-BP). Time from baseline to remission is defined as the primary efficacy measure. Remission is defined as a Y-MRS score \<=12 AND a MADRS-S score \<=12 AND CGI-BP = 1 or 2.

Secondary efficacy assessments will include time from baseline to

  • Response, as defined as a reduction of Y-MRS score greater than or equal to 50% compared to baseline
  • Relapse of mania, as defined as a Y-MRS score >= 16 AND CGI-BP >2 after having met the criteria for remission
  • Switch into depression, as defined as a MADRS-S score >=17 AND fulfilled criteria for Major Depression as self-assessed by DSRS.
03

Conditions studied

  • Bipolar Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of bipolar I disorder and currently display an acute manic or mixed episode (with or without psychotic features)
  • Patients must have a Y-MRS total score of greater or equal to 20 at visit 2
  • Patients must have experienced at least one manic or mixed episode prior to study enrollment
  • Female of must be using a medically accepted means of , or practice sexual abstinence
  • Each patient must have a level of understanding sufficient to communicate intelligently with study personnel
  • Patients must be considered reliable
  • Each patient must understand the nature of the study and signed

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or lactating
  • Serious, unstable illnesses such that hospitalization for the disease is anticipated within 3 month or death is anticipated within 3 years
  • Uncorrected hypothyroidism or hyperthyroidism
  • Narrow-angle glaucoma
  • History of allergic reactions or intolerance to study medications
  • substance dependence within the past 30 days at the judgement of the investigator
  • Judged clinically to be at serious suicidal risk
  • Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to visit 2
  • Any patient treated with clozapine within 4 weeks prior to visit 2
  • Subjects who have received treatment with ECT within one month prior to visit 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    A

    Patients will be given olanzapine

    Drug: olanzapine

  • Active comparator
    B

    Patients will be given either haloperidol or zuclopentixol

    Drug: haloperidol · Drug: zuclopentixol

Interventions

  • physician determined dose, oral, daily, 5 months

    Also known as: LY170053, Zyprexa

  • physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months

  • physician determined dose, oral, parenteral (\<= 3 days), daily, 5 months

06

What researchers measure

Primary outcomes

  1. Time to remission by Young Mania Rating Scale, MADRS-S and CGI-BP

    Time frame: 5 months

Secondary outcomes

  1. Resource utilization Clinical Report Form (RUCRF)

    Time frame: 5 months

  2. Disability free day assessment (DFDA)

    Time frame: 5 months

  3. Medication compliance

    Time frame: 5 months

  4. Medical Outcomes Study 36-Item Short Form Health Survey (SF-36)

    Time frame: 5 months

  5. Euro Qol instrument

    Time frame: 5 months

  6. Drug Attitude Inventory (DAI)

    Time frame: 5 months

  7. Response by Y-MRS

    Time frame: 5 months

  8. Frequency of and time to relapse into mania by Y-MRS and CGI-BP

    Time frame: 5 months

  9. Frequency of and time to switch to depression by MADRS-S and DSRS

    Time frame: 5 months

  10. Time to remission in patients with psychotic features by SCID-I judgement, Y-MRS item 8 and PANSS positive items mean sum

    Time frame: 5 months

  11. Adverse events

    Time frame: 5 months

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Danderyd, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2008
First posted
Oct 7, 2008
Start
Oct 2004
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Oct 7, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00767715
First posted
Oct 7, 2008
Start date
Oct 2004
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Oct 7, 2008

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion